A phase II study of AZD2171 [cediranib] in adult patients with neurofibromatosis type 1 and extensive plexiform and paraspinal neurofibromas

Trial Profile

A phase II study of AZD2171 [cediranib] in adult patients with neurofibromatosis type 1 and extensive plexiform and paraspinal neurofibromas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs Cediranib (Primary)
  • Indications Cancer; Neurofibromatoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 May 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 May 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 13 May 2014 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top